In 2010, liraglutide97% homologous to human GLP-1was approved first for diabetes and later for obesity in 2014, while semaglutide, also a modified GLP-1 analogue, now treats both conditions 5
Starting with tirzepatide at conservative doses provides a safer entry point for this population
Negative reviews frequently report skin irritation, rashes, blisters, and no change in weight
Lixisenatide was also approved during that timeframe, for use in Europe [31]
However, they were linked to an increased risk of headache in women with PCOS
For weight management, NICE has appraised several licensed medicines that are available through NHS pathways or regulated private clinics: Semaglutide (Wegovy) NICE Technology Appraisal TA875 recommends semaglutide as an option for managing overweight and obesity in adults with a BMI of 35 kg/m or more (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service